The past and future of antibodies, as told through HIV; Another big pharma joins CD47 game; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Jason Mast’s deeply reported special on antibody development should keep you quite busy, but if you want to dive deeper into the topic over the weekend, be sure to check out the webinar discussion with top experts in the field, moderated by Kyle Blankenship.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.